Sinphar Pharmaceutical Co (TPE:1734) Total Equity: NT$3,715 Mil (As of Dec. 2025)


TPE:1734 Sinphar Pharmaceutical Co Ltd TPE:1734
81 GF Score
Price NT$33.80
GF Value NT$33.15
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Sinphar Pharmaceutical Co Total Equity?

Sinphar Pharmaceutical Co TPE:1734 +0.60% 81 Total Equity is NT$3,715 Mil as of Dec. 2025. GuruFocus rates TPE:1734 with a GF Score™ of 81/100 and a GF Value™ of NT$33.15 (Fairly Valued). The stock has 2 warning signs investors should review.

Sinphar Pharmaceutical Co's total equity for the quarter that ended in Dec. 2025 was NT$3,715 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Sinphar Pharmaceutical Co Total Equity Historical Data

* Premium members only.

The historical data trend for Sinphar Pharmaceutical Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinphar Pharmaceutical Co Total Equity Chart

Sinphar Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,077.18 3,216.85 3,397.87 3,546.18 3,715.18

Sinphar Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,546.18 3,671.61 3,458.70 3,573.09 3,715.18
TPE:1734
81GF Score
Sinphar Pharmaceutical Co Ltd TPE:1734
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinphar Pharmaceutical Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Sinphar Pharmaceutical Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=6153.05-2437.873
=3,715

Sinphar Pharmaceutical Co's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=6153.05-2437.873
=3,715

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$3,715 Mil mean?
Sinphar Pharmaceutical Co (TPE:1734) has a Total Equity of NT$3,715 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Sinphar Pharmaceutical Co and its competitors.
Is Sinphar Pharmaceutical Co's Total Equity too high?
Sinphar Pharmaceutical Co's current Total Equity is NT$3,715 Mil. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's Total Equity compare to VRTX and REGN?
Sinphar Pharmaceutical Co's Total Equity of NT$3,715 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Sinphar Pharmaceutical Co and its competitors. Sinphar Pharmaceutical Co's current Total Equity is NT$3,715 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.15, compared to a current price of NT$33.80 — trading 2% above its estimated fair value. The current Total Equity is NT$3,715 Mil. Sinphar Pharmaceutical Co's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current Total Equity is NT$3,715 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?

Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be overvalued. The current stock price of NT$33.80 is trading 2% above its estimated GF Value™ of NT$33.15. GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TPE:1734:

  • Total Equity: NT$3,715 Mil
  • GF Value™: NT$33.15 vs. price of NT$33.80 (2% above fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinphar Pharmaceutical Co Business Description

Address No.84, Zhongshan Road, Dongshan Township, Zhongshan Village, Yilan, TWN, 269
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
81GF Score

Get the complete analysis for TPE:1734

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$33.80
Price
NT$33.15
GF Value